Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNLs and Camrelizumab for Advanced HER2-Negative Breast Cancer
NCT06121557Phase 1Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tumor-draining lymph node-derived lymphocytes in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicity at 28 days and Incidence of Grade >=3 Treatment-Emergent Adverse Event at 28 days. Started Nov 2023; status: recruiting.
02
Drugs
tumor-draining lymph node-derived lymphocytes
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06121557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06121557.